LEADER 01307nam  2200421   450 
001 9910155225203321
005 20171118134639.0
010   $a1-5361-0398-5
035   $a(CKB)3710000000973854
035   $a(MiAaPQ)EBC4787081
035   $a(EXLCZ)993710000000973854
100   $a20170127h20172017  uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aAntidepressants $eperspectives, medical uses and health implications /$fSharon Jenkins, editor
210  1$aNew York :$cNova Biomedical,$d2017.
210  4$dİ2017
215   $a1 online resource (171 pages) $cillustrations
225 1 $aPharmacology - Research, Safety Testing and Regulation
311   $a1-5361-0381-0 
320   $aIncludes bibliographical references at the end of each chapters and index.
410  0$aPharmacology-research, safety testing, and regulation series.
606   $aAntidepressants
606   $aDepression, Mental
615  0$aAntidepressants.
615  0$aDepression, Mental.
676   $a615.78
702   $aJenkins$b Sharon
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910155225203321
996   $aAntidepressants$91764244
997   $aUNINA